CRISPR Ther­a­peu­tics, Case­bia ink AAV deal with Stride­Bio; Puma gets an Ad­Comm date; Mer­ri­mack names new R&D chief

→ CRISPR Ther­a­peu­tics $CR­SP and Case­bia Ther­a­peu­tics, a joint-ven­ture es­tab­lished by CRISPR Ther­a­peu­tics and Bay­er AG, have inked a col­lab­o­ra­tion agree­ment with Stride­Bio to de­vel­op AAV vec­tors for in vi­vo gene de­liv­ery ap­pli­ca­tions. Stride­Bio’s task will be to de­vel­op “vec­tors with im­proved prop­er­ties such as tis­sue speci­fici­ty and re­duced sus­cep­ti­bil­i­ty to im­mune re­spons­es.”

→ The On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee (ODAC) will meet on May 24 to dis­cuss Puma’s $PBYI ap­pli­ca­tion for its can­cer drug ner­a­tinib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER